Covovax receives WHO approval for emergency use
The World Health Organisation on Friday approved emergency use listing of Covid vaccine Covovax, produced by the Serum Institute of India under licence from Novavax and part of the Covax facility portfolio.
The World Health Organisation on Friday approved emergency use listing of Covid vaccine Covovax, produced by the Serum Institute of India under licence from Novavax and part of the Covax facility portfolio.
"This is yet another milestone in our fight against Covid-19. Covovax is now WHO approved for emergency use, showing excellent safety and efficacy. Thank you all for a great collaboration," Serum Institute of India CEO Adar Poonawala said.
See Zee Business Live TV Streaming Below:
Covovax has a two-dose regimen and is the ninth to receive emergency use approval from the WHO. However, it is yet to be granted emergency use authorisation (EUA) by the top drug regulator, the DCGI, in India.
The listing aims to increase access particularly in lower-income countries, 41 of which have still not been able to vaccinate 10 per cent of their populations, while 98 countries have not reached 40 per cent, said the global health body.
Covovax was assessed under the WHO EUL procedure based on the review of data on quality, safety and efficacy, a risk management plan, programmatic suitability, and manufacturing site inspections carried out by the Drugs Controller General of India.
The Technical Advisory Group for Emergency Use Listing (TAG-EUL), convened by the WHO and made up of experts from around the world, has determined that the vaccine meets WHO standards for protection against Covid-19, that the benefit of the vaccine far outweighs any risks, and that the vaccine can be used globally, the WHO said in a statement.
The Covovax vaccine, developed by the SII in partnership with the US-based Novavax, is the third India-related vaccines to be approved by the WHO. The other two vaccines are Covishield and Covaxin. Covaxin is India`s first indigenous Covid vaccines, while Covishield is Indian version of Britain`s AstraZeneca jab.
Get Latest Business News, Stock Market Updates and Videos; Check your tax outgo through Income Tax Calculator and save money through our Personal Finance coverage. Check Business Breaking News Live on Zee Business Twitter and Facebook. Subscribe on YouTube.
RECOMMENDED STORIES
SBI Senior Citizen Latest FD Rates: What senior citizens can get on Rs 7 lakh, Rs 14 lakh, and Rs 21 lakh investments in Amrit Vrishti, 1-, 3-, and 5-year fixed deposits
SBI Guaranteed Return Scheme: Know how much maturity amount you will get on Rs 2 lakh, 2.5 lakh, 3 lakh, 3.5 lakh and Rs 4 lakh investments under Amrit Vrishti FD scheme
Power of Compounding: How soon will monthly SIP of Rs 6,000, Rs 8,000, and Rs 10,000 reach Rs 5 crore corpus target?
SIP+SWP: Rs 10,000 monthly SIP for 20 years, Rs 25 lakh lump sum investment, then Rs 2.15 lakh monthly income for 25 years; see expert calculations
SBI Senior Citizen FD Rate: Here's what State Bank of India giving on 1-year, 3-year, 5-year fixed deposits currently
09:58 PM IST